Collegium Pharmaceutical, Inc. (COLL) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

75OpportunityDD: Jun 19, 2026Analyst: 75

paidPrice at analysis date

USD 33.7 (19/06/2026)

domainMkt cap

$1.09B

pie_chartShares

32.43M

candlestick_chart52W

$29.08-$50.79

trending_downShort interest

17.8%

INFONASDAQHealth Care423 employeesFounded 2002

Verdict: Favorable Risk/Reward —

Cash-generative specialty pharma with reaffirmed FY26 guide ($805–825M revenue / $455–475M adj EBITDA), Q1'26 beat (+8% EPS, +5% revenue) and recently-closed AZSTARYS acquisition extending ADHD franchise exclusivity to 2037. Trading at ~3.9x EV/EBITDA forward vs specialty pharma peer median ~6–7x; multiple compression reflects opioid-portfolio overhang and integration risk. Asymmetric value setup with limited downside from EBITDA floor.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-19

Collegium Pharmaceutical, Inc. (COLL)

Specialty Pharma · NASDAQ · Stoughton, MA

"Cash flow compounder at value multiple — re-rating contingent on AZSTARYS integration and opioid-tail clarity."

FCF positive JORNAY PM +36% Forward P/E ~6x SI 17–18% Opioid overhang

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — EV/EBITDA SotP (ADHD + Pain franchises)

Fair value base case

USD 49.5

Range: USD 28.0-USD 70.0

Price at analysis date: USD 33.7 (19/06/2026)

Base upside/downside: +47%

Methodology: EV/EBITDA SotP applied to two franchises (ADHD growth vs Pain mature) with peer-derived multiples; net debt and opioid litigation reserve as separate equity bridges. Sensitivity: ±1.0x multiple on ADHD franchise moves FV ±$6.8/sh (≈14%); ±1.0x on Pain moves FV ±$7.9/sh (≈16%); +$200M incremental opioid liability moves FV −$6.2/sh. Primary multiple-implied check passed (5.2x vs nominal 6.0x = −13%, within ±20% tolerance). Secondary check via forward P/E (8x peer → $48.6) within ±2%. ⚠️ Not investment advice.

Component	Assumption	USD/share
ADHD franchise EV (JORNAY PM + AZSTARYS)	$220M FY26E adj EBITDA × 6.5x EV/EBITDA (growth premium vs peer median, exclusivity to 2037)	+44.10
Pain portfolio EV (Xtampza, Belbuca, Nucynta)	$255M FY26E adj EBITDA × 4.0x EV/EBITDA (mature/declining, generic tail risk 2027+)	+31.50
Net debt	−$700M (≈$980M credit facility drawn post-AZSTARYS less ~$280M cash) / 32.43M shares	−21.60
Buyback contribution (FY26E)	~$50M repurchases / 32.43M, accretion @ current multiple	+0.80
Opioid litigation reserve	−$170M expected liability NPV (probability-weighted, 30% × $560M) / 32.43M	−5.30
FV base case	Sum: +44.10 +31.50 −21.60 +0.80 −5.30	≈ $49.50

Bull

$60–70

Probability: 25%

JORNAY PM crosses $200M revenue, AZSTARYS integration smooth and accretive, opioid MDL settles below $200M total exposure. Multiple expands to peer median 6x. Buyback accelerates as deleveraging hits 1.0x.

Base

$45–55

Probability: 50%

FY26 guidance hit (mid-range), pain franchise declines 4–6%/yr, AZSTARYS contributes $30–40M EBITDA Y1. Multiple expands moderately to 4.5–5.0x as integration de-risks. Consensus $54 reachable.

Bear

$25–32

Probability: 25%

JORNAY PM growth decelerates below 20% YoY, pain franchise generics accelerate (early 2027 Belbuca/Nucynta erosion), opioid MDL settlement exceeds $500M. Net debt remains >2x EBITDA into 2027, no buyback.

Methodology: Methodology: EV/EBITDA SotP applied to two franchises (ADHD growth vs Pain mature) with peer-derived multiples; net debt and opioid litigation reserve as separate equity bridges. Sensitivity: ±1.0x multiple on ADHD franchise moves FV ±$6.8/sh (≈14%); ±1.0x on Pain moves FV ±$7.9/sh (≈16%); +$200M incremental opioid liability moves FV −$6.2/sh. Primary multiple-implied check passed (5.2x vs nominal 6.0x = −13%, within ±20% tolerance). Secondary check via forward P/E (8x peer → $48.6) within ±2%. ⚠️ Not investment advice. Not investment advice.

📊 Capital Structure · Short Interest · Buyback & Dilution

🔴 Short Interest

~17.8%

~5.19M shares short / ~31.6M float. Days to cover: ~13.5 (avg vol 330K). Elevated for a profitable specialty pharma — partly opioid-bear thesis, partly skepticism on AZSTARYS deal economics.

🟢 Share dilution (1Y)

−2.1%

From ~33.1M to ~32.4M shares outstanding. Cause: ongoing buyback program offsetting inducement grants. Net reduction signals capital discipline.

🟡 Buyback

Active

$980M credit facility prioritizes deleveraging post-AZSTARYS, but opportunistic buybacks confirmed by mgmt. ~$50M expected in FY26 vs $650M cash deployed to M&A.

Short Interest — context

COLL — 17.8%

17.8%

Insider activity (last 12 months): EVP/CMO Thomas Smith sold ~$672K at $38.42 avg; Director Nancy Lurker sold $162K at $35.97 (20% of holding); Director John Gordon Freund sold 4,127 shares @ $34.54 on 2026-05-15. No insider buying. Pattern suggests partial profit-taking after multi-year rally rather than insider distress. Combined SI + insider selling create technical headwind but also asymmetric squeeze potential if AZSTARYS execution beats.

$Financial analysis — FY 2026

Revenue FY25

$780.6M

+23.6% YoY

FY26 Revenue Guide

$805–825M

+3–6% YoY (organic + AZSTARYS Q2 partial)

FY26 Adj EBITDA Guide

$455–475M

~58% margin

Net Income FY25

$62.9M

−9.1% YoY (M&A costs)

Item	FY2023	FY2024	FY2025	Q1 2026	Guidance 2026
Revenue ($M)	568	631	781	193.5	805–825
YoY growth %	+18%	+11%	+24%	+9%	+3–6%
Adj EBITDA ($M)	355	395	435	112	455–475
Adj EBITDA margin %	62%	63%	56%	58%	57%
Net income ($M)	27	69	63	14	N/D — guidance EBITDA only
JORNAY PM revenue ($M)	—	~85	~130	38.9 (+36% YoY)	~175–200

Note: FY25 EBITDA margin compression reflects AZSTARYS deal advisory costs and JORNAY PM commercial scale-up; FY26 guide assumes margin normalization. Net income reflects high D&A from prior acquisitions.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	177.3	185.0	199.8	218.5	193.5
Adj EBITDA margin %	62%	61%	58%	54%	58%
Net income ($M)	15.4	17.8	14.6	15.1	14.0
End-of-period cash ($M)	185	205	225	280	295

Financial position and sustainability

FCF generation (FY25)

~$320M

Net debt/EBITDA post-AZSTARYS

~1.5x

JORNAY PM YoY growth

+36%

Pain portfolio YoY trend

~−2%

account_tree

Business model — Specialty pharma with dual franchise (Pain + ADHD)

Diversified specialty pharma with a clear growth lever

Collegium operates two distinct franchises: (1) a mature Pain Management portfolio (Xtampza ER, Belbuca, Nucynta ER/IR) generating ~65% of revenue with declining-to-flat trajectory but high cash conversion; (2) a high-growth ADHD franchise centered on JORNAY PM (+36% YoY) recently expanded via the $650M AZSTARYS acquisition (closed 2026-05-12), extending franchise exclusivity to 2037 and adding cross-selling capacity. FY26 guidance reaffirmed at $805–825M revenue and $455–475M adj EBITDA. Capital allocation prioritizes deleveraging post-AZSTARYS, with opportunistic buybacks. Sales force integration on track per Jefferies conference commentary (June 2026).

ADHD Franchise (JORNAY PM + AZSTARYS) ~$240–270M FY26E (≈32% rev) 🟢 ramping JORNAY PM (delayed-release methylphenidate) growing +36% YoY. AZSTARYS (serdexmethylphenidate) adds differentiated profile + exclusivity to 2037. GM target >85%. Risk: cross-selling integration execution. Xtampza ER (abuse-deterrent oxycodone) ~$165–180M FY26E (≈22% rev) 🟡 stable Abuse-deterrent formulation, market-leading position. Stable script volumes, modest price erosion. GM ~80%. Generic competition contained (no AB-rated generic). Key cash cow. Belbuca + Nucynta (Pain tail) ~$345–380M FY26E (≈46% rev) 🔴 declining Belbuca (buccal buprenorphine) faces ~5–7%/yr erosion. Nucynta ER/IR generic exposure starting 2027. Critical to manage cash extraction during runoff. GM ~75%.

gavel

Legal, regulatory and risk analysis

Opioid litigation tail

High

Multi-district MDL settlements have hit larger players; COLL has modest opioid exposure but reserve uncertainty remains. Reserved $170M NPV (probability-weighted) — could swing ±$200M.

Pain portfolio generic erosion

Moderate

Nucynta ER LOE 2027, Belbuca facing extended-release competition. Manageable: 46% of revenue but EBITDA margin already factored. Risk if generics accelerate vs base case.

AZSTARYS integration execution

Moderate

$650M deal closing 2026-05-12. Cross-selling synergies depend on sales force integration. Management track record solid (prior BDSI deal accretive within 12 months) but binary on outcome.

Leverage post-acquisition

Moderate

Net debt/EBITDA jumped from ~0.3x to ~1.5x after AZSTARYS. Manageable given $475M EBITDA, but limits capital flexibility and buyback aggressiveness for 12–18 months.

JORNAY PM franchise concentration

Moderate

Single ADHD asset drives growth thesis. Competitive ADHD landscape (Vyvanse generics, new launches). AZSTARYS partially mitigates by adding second asset.

JORNAY PM growth durability

Positive

36% YoY growth with multi-year exclusivity (2030+). Pediatric ADHD market underpenetrated. Positive risk: growth can accelerate if AZSTARYS halo effect boosts ADHD share.

Cash generation predictability

Positive

~$320M FCF FY25 with low capex (~$15M). Deleveraging path clear: 12–18 months to return to <1x net debt/EBITDA. Optionality for future M&A or buyback acceleration.

Valuation discount vs peers

Positive

3.9x EV/EBITDA fw vs peer median 5.8x = 33% discount. Even partial closure of this gap (to ~5.0x) implies +25–30% re-rating without earnings revision.

article

SWOT analysis

Strengths

+Cash-generative platform: ~$320M FCF FY25, 57% adj EBITDA margin guide FY26
+JORNAY PM growth franchise: +36% YoY, exclusivity to 2030+
+AZSTARYS extends ADHD exclusivity to 2037, immediately EBITDA accretive
+Diversified specialty asset base (4+ commercial products)
+Disciplined capital allocation: net dilution −2% via buybacks

Weaknesses

−Pain franchise (46% rev) in structural decline, generics 2027+
−Net debt jumped to ~1.5x EBITDA post-AZSTARYS, limits flexibility
−Opioid litigation reserve uncertainty ($170M base, ±$200M tail)
−Insider selling pattern (no buying in 12 months)
−Single growth asset (JORNAY) drives the entire valuation re-rating thesis

Opportunities

→Multiple expansion: 3.9x → 5.5x peer-median EV/EBITDA = +30% re-rating
→AZSTARYS cross-sell could push ADHD franchise above $300M FY27
→Deleveraging path enables resumed/accelerated buyback by 2027
→Additional bolt-on ADHD or CNS M&A using $980M facility headroom

Threats

!Accelerated opioid MDL settlements above $500M total exposure
!FDA/DEA tightening on opioid prescribing impacts pain portfolio
!Generic launches earlier than expected for Belbuca/Nucynta
!ADHD competitive entry (Vyvanse generics, new mechanisms)

article

Summary by assessment area

🟢 Financial risk — Low

FCF positive ~$320M FY25
Net debt 1.5x EBITDA, manageable
Adj EBITDA $455–475M FY26 guide

🟡 Execution risk — Moderate

AZSTARYS integration is key swing factor
JORNAY PM growth sustainability
Pain franchise runoff management

🔴 Tail risk — Opioid + Generic

Opioid litigation NPV ±$200M
Nucynta/Belbuca generics 2027+
DEA/FDA opioid regulation tightening

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "Specialty pharma cash-generative a 3,9x EV/EBITDA forward vs peer median 5,8x. JORNAY PM +36% YoY, AZSTARYS estende esclusivita' ADHD al 2037. FV base $49,50 vs prezzo $33,71 (+47%).", "en": "Cash-generative specialty pharma at 3.9x forward EV/EBITDA vs peer median 5.8x. JORNAY PM +36% YoY, AZSTARYS extends ADHD exclusivity to 2037. Base FV $49.50 vs price $33.71 (+47%)."}, "bull_points": [ {"it": "FY26 guide riconfermata: $805-825M ricavi, $455-475M adj EBITDA (margine ~57%).", "en": "FY26 guide reaffirmed: $805-825M revenue, $455-475M adj EBITDA (~57% margin)."}, {"it": "JORNAY PM +36% YoY, AZSTARYS aggiunge esclusivita' ADHD al 2037.", "en": "JORNAY PM +36% YoY, AZSTARYS adds ADHD exclusivity to 2037."}, {"it": "Sconto del 33% sul multiplo EV/EBITDA peer median: ampio margine di re-rating.", "en": "33% discount on peer-median EV/EBITDA multiple: ample re-rating headroom."} ], "bear_points": [ {"it": "Portafoglio Pain (46% ricavi) in declino strutturale, generici Nucynta 2027.", "en": "Pain portfolio (46% rev) in structural decline, Nucynta generics 2027."}, {"it": "Leva netta salita a ~1,5x EBITDA dopo AZSTARYS ($650M cash).", "en": "Net leverage rose to ~1.5x EBITDA post-AZSTARYS ($650M cash)."}, {"it": "Riserva litigation opioid incerta ($170M NPV, coda +/-$200M).", "en": "Opioid litigation reserve uncertain ($170M NPV, tail +/-$200M)."} ], "risks": [ {"it": "Short interest ~17.8% e insider selling cumulativo: pressione tecnica.", "en": "Short interest ~17.8% and cumulative insider selling: technical pressure."}, {"it": "Esecuzione integrazione AZSTARYS binaria sulla tesi di crescita.", "en": "AZSTARYS integration execution is binary for the growth thesis."}, {"it": "Accelerazione generici Belbuca/Nucynta o settlement opioid >$500M.", "en": "Acceleration of Belbuca/Nucynta generics or opioid settlement >$500M."} ] }

Sources & Disclaimer

Sources: stockanalysis.com (COLL overview, statistics, financials), Yahoo Finance (close price 2026-06-18), Simply Wall St (insider activity, peer valuation), Fintel/Stocktitan (short interest, Form 4), GlobeNewswire (Q1 2026 release, AZSTARYS acquisition press), Investing.com (Q1 2026 earnings call transcript), Jefferies Global Healthcare Conference transcript (June 2026), MarketBeat (analyst consensus). Market data — last verified close 2026-06-18: COLL ~$33.71, market cap ~$1.09B, 52W range $29.08–$50.79, ~32.43M shares outstanding. Short interest: ~17.8% of float, ~13.5 days to cover. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.